Market cap
$2.1b
End-of-day close multiplied by current shares on issue.
SUM · NZX
Summerset Group Holdings is an NZX-listed healthcare / retirement living company with FY22 - FY25 of published result briefings.
Snapshot
FY25, released 27 February 2026
| Metric | Value | Change |
|---|---|---|
| Revenue | $361.8m | ↑ +13.1% |
| NPAT | $259.7m | ↓ -23.6% |
| Operating cash flow | $548.2m | ↑ +23.7% |
| Net debt | $2b | ↑ +15.4% |
| ROE % | 7.8%Outside range low roe. 7.8%; 3-period range 11.5% to 16.8%. ROE: 7.8%, below normal range; 3-period mean 13.5%, range 11.5%-16.8%. | ↓ -3.6pp |
| DPS | 13.2c | — Flat |
| Payout ratio vs NPAT % | 22.7% | ↑ +5.8pp |
| Annual payout ratio vs EPS % | 22.7% | ↑ +5.8pp |
| PBT | $241.1m | ↓ -32.2% |
| FCF pre-lease | -$98.9m | ↑ +41.2% |
Source: latest published briefing (FY25, released 27 February 2026). Change compares against the prior equivalent period: FY24, released 28 February 2025.
Valuation
A compact read on what the market price implies next to the latest filing data. The numbers are a starting point for comparison, not a recommendation.
The latest close and share count context for the market price.
Market cap
$2.1b
End-of-day close multiplied by current shares on issue.
How the market price compares with recent earnings and cash-flow inputs.
P/E
8.07x
Recent market cap compared with trailing earnings.
EPS
1.06
Recent filing-derived earnings per share.
PEG
Not available
Not meaningful without positive comparable earnings growth.
EV/EBITDA
Not available
Not available for this company right now.
P/FCF
Not available
Not meaningful when free cash flow is negative or unavailable.
P/B
0.63x
Market value compared with latest reported equity.
Yield and fund-style valuation where the company shape supports it.
Dividend yield
2.9%
Trailing dividends compared with the latest close.
Total return
Not available
Available once dividend and adjustment data are verified.
Daily closes use the full available width, with hover and touch readouts against real observations. Expand opens the chart at reading size.
Five years of daily closes, as at close, 5 June 2026. Weekends, suspensions, and listing gaps stay as natural gaps in the time scale.
Indexed lines compare direction from the first positive comparable filing point. The axis is an index, not dollars or cents.
Chat
Ask follow-up questions about Summerset Group Holdings's latest result and company history.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Longitudinal view
The latest period is shown first.
| Metric | FY2512 MONTHS27 February 2026 | HY256 MONTHS28 August 2025 | FY2412 MONTHS28 February 2025 | HY246 MONTHS26 August 2024 | FY2312 MONTHS26 February 2024 | HY236 MONTHS23 August 2023 | FY2212 MONTHS24 February 2023 | Trend |
|---|---|---|---|---|---|---|---|---|
| Revenue | $361.8m | $173m | $319.9m | $151.6m | $272.2m | $128.2m | $238.7m | Chart |
| Revenue growth % | 13.1%Outside range low revenue growth. 13.1%; 3-period range 14% to 17.5%. Revenue growth: 13.1%, below normal range; 3-period mean 15.9%, range 14.0%-17.5%. | 14.1% | 17.5%Outside range high revenue growth. 17.5%; 3-period range 13.1% to 16.2%. Revenue growth: 17.5%, above normal range; 3-period mean 14.4%, range 13.1%-16.2%. | 18.2% | 14.0% | 12.4% | 16.2% | Chart
|
| EBITDA | — | $135.8m | $382.1m | $133.5m | $450m | $140.7m | $282.1m | Chart |
| EBITDA margin % | — | 78.5% | 119.4% | 88.0% | 165.3% | 109.7% | 118.2% | Chart |
| PBT | $241.1m | $109.8m | $355.8m | $120.8m | $422.5m | $128.1m | $265.1m | Chart |
| PBT growth % | -32.2% | -9.1% | -15.8% | -5.7% | 59.4%Outside range high pbt growth. 59.4%; 3-period range -51.2% to -15.8%. PBT growth: 59.4%, above normal range; 3-period mean -33.1%, range -51.2%--15.8%. | -5.0% | -51.2%Outside range low pbt growth. -51.2%; 3-period range -32.2% to 59.4%. PBT growth: -51.2%, below normal range; 3-period mean 3.8%, range -32.2%-59.4%. | Chart
|
| NPAT | $259.7m | $127.2m | $339.8m | $102.2m | $436.3m | $133.1m | $269.1m | Chart |
| NPAT growth % | -23.6% | 24.5% | -22.1% | -23.2% | 62.1%Outside range high npat growth. 62.1%; 3-period range -50.5% to -22.1%. NPAT growth: 62.1%, above normal range; 3-period mean -32.1%, range -50.5%--22.1%. | -1.1% | -50.5%Outside range low npat growth. -50.5%; 3-period range -23.6% to 62.1%. NPAT growth: -50.5%, below normal range; 3-period mean 5.5%, range -23.6%-62.1%. | Chart
|
| Operating cash flow | $548.2m | $228.7m | $443.2m | $191.6m | $398.2m | $146.7m | $369.2m | Chart |
| OCF / EBITDA % | — | 168.4% | 116.0% | 143.5% | 88.5% | 104.2% | 130.9% | Chart |
| FCF pre-lease | -$98.9m | -$17.7m | -$168.2m | -$63.9m | $66.3m | $117.2m | -$264.7m | Chart |
| FCF post-lease | — | -$17.7m | — | — | $66.3m | — | -$14.7m | Chart |
| DPS | 13.2c | 11.3c | 13.2c | 11.3c | 13.2c | 11.3c | 11.6c | Chart |
| Payout ratio vs NPAT % | 22.7% | 21.3% | 16.9% | 26.0% | 13.1% | 19.7% | 19.1% | Chart |
| Annual payout ratio vs EPS % | 22.7% | — | 16.9% | — | 13.1% | — | 19.1% | Chart |
| ROE % | 7.8%Outside range low roe. 7.8%; 3-period range 11.5% to 16.8%. ROE: 7.8%, below normal range; 3-period mean 13.5%, range 11.5%-16.8%. | 4.0% | 11.4% | 3.8% | 16.8%Outside range high roe. 16.8%; 3-period range 7.8% to 12.3%. ROE: 16.8%, above normal range; 3-period mean 10.5%, range 7.8%-12.3%. | 5.8% | 12.3% | Chart
|
| Net debt | $2b | $1.8b | $1.7b | $1.5b | $1.4b | $1.3b | $1b | Chart |
| Net debt / EBITDA | — | 13.62x | 4.46x | 11.44x | 3.07x | 9.04x | 3.72x | Chart |
| Debtor days | 9Outside range high debtor days. 9d; 3-period range 7d to 8d. Debtor days: 9.1 days, above normal range; 3-period mean 7.5 days, range 6.9 days-8.3 days. | 51 | 8 | 56 | 7Outside range low debtor days. 7d; 3-period range 7d to 9d. Debtor days: 6.9 days, below normal range; 3-period mean 8.2 days, range 7.2 days-9.1 days. | 58 | 7 | Chart
|
| Total assets | $9.2b | $8.7b | $8.1b | $7.4b | $6.9b | $6.3b | $5.8b | Chart |
Reference: annolyse.ai/companies/sum
Note: Figures are shown as reported. Half-year and full-year absolute values are not directly comparable. Growth rates and ratios are the meaningful comparison across mixed periods.
These charts use verified published filing periods only. Gaps are not interpolated, and mixed half-year/full-year histories are split into separate series.
Reported revenue across covered periods.
Like-period revenue growth where comparable.
Company-specific earnings measure where disclosed.
EBITDA-equivalent margin where revenue and earnings are source-backed.
Statutory profit after tax.
Cash generated from operations.
Additional verified filing metrics for this company. Each point links back to a published briefing period in the source data contract.
Cash conversion against earnings.
Operating cash flow less capex before leases.
Free cash flow after lease payments where available.
Return on equity.
Borrowings less cash; negative values indicate net cash.
Leverage ratio, suppressed where earnings are not meaningful.
Dividend per share declared for the period.
Dividend payout against statutory NPAT.
Receivables days where the working-capital inputs are source-backed.
Per-period working-capital absorption or release, from the same published history. Positive values are working-capital build; negative values are release.
The setup & the reality
The latest result is checked against what the prior briefing said to watch.
Historical setup
From Underlying profit +19% on 692 sales, but NPAT flattered by tax swing
No quantified FY25 guidance is supplied. Seasonality is meaningful: HY24 represented 47.4% of FY24 revenue but only 30.1% of FY24 NPAT, because IFRS fair value movements concentrate at year-end. Annualising HY25 revenue gives roughly $346m, but reported NPAT will likely step up materially in 2H25 from year-end revaluations rather than from operating mix.
Management commentary states the FY25 outlook is "improving as positive sales momentum continues." The release does not provide forward sales, contracted occupation rights, or a development margin target, so a quantitative second-half check from this disclosure alone is not possible.
Open questions
This briefing cannot assess whether the current sales velocity reflects a structural recovery in retirement housing demand or a cyclical bounce off a softer HY24 comparable.
Archive
Every published Annolyse briefing for this company appears here in reverse chronological order.
FY25 · Released 27 February 2026
IFRS earnings dropped on lower investment property fair-value uplifts, masking a 26% jump in unit settlements and 23.7% rise in operating cash flow.
HY25 · Released 28 August 2025
OCF rose 19.3% to $228.7m and gross borrowings grew 21.3% to $1.87b as $311.6m of development capex left free cash flow at -$17.7m.
FY24 · Released 28 February 2025
Statutory NPAT fell 22.1% on smaller fair-value gains while gross borrowings rose 23% to fund a NZ$611.4m build programme.
HY24 · Released 26 August 2024
A surge in development capex to $255.6m flipped free cash flow to -$63.9m and pushed net debt to $1,527.3m despite stronger occupation-rights cash
FY23 · Released 26 February 2024
Underlying profit of NZ$190.3m and 1,103 ORA sales describe a steadier operational result than the headline IFRS NPAT, while net debt rose NZ$332m.
HY23 · Released 23 August 2023
Underlying profit lifted 5.7% to $87.2m but reported NPAT slipped 1.1% as fair-value gains shrank and capex climbed 24.9%.
FY22 · Released 24 February 2023
Development capex of $633.8m pushed gross borrowings to $1.07b and free cash flow to -$14.7m, with operating cash flow still near prior-year levels.
Get the next Summerset Group Holdings result briefing and five-year history updates by email.